LEVEMIR FLEXTOUCH 100 UNIT — DIN 02412829
INSULIN DETEMIR : 100 UNIT · NOVO NORDISK CANADA INC · SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is LEVEMIR FLEXTOUCH?
LEVEMIR FLEXTOUCH 100 UNIT contains INSULIN DETEMIR : 100 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02412829, held by NOVO NORDISK CANADA INC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as cancelled post market, status dated 04-Aug-2023. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is LEVEMIR FLEXTOUCH used for?
Treatment of type 1 diabetes (adults/pediatrics 2+ years) and type 2 diabetes in adults, including in combination with oral anti-diabetic agents or GLP-1 receptor agonists.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Insulin Detemir cost around the world?
Insulin Detemir is listed on 3 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Greece publishes a producer price (ex-factory); Norway publishes a max AUP (pharmacy retail); South Africa publishes a single exit price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| Greece | producer price (ex-factory) | 41 | 41 |
| Norway | max AUP (pharmacy retail) | 5 | 6 |
| South Africa | single exit price | 1 | 2 |
49 pack listings across 47 brand entries and 3 price bases, refreshed 07 Sep 2026. Ranges span every Insulin Detemir pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Insulin Detemir in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Insulin Detemir — 2 DINs, of which 0 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| NOVO NORDISK CANADA INC | 2 | 0 | LEVEMIR FLEXTOUCH, LEVEMIR PENFILL | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 100 UNIT |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS |
| Pack configuration (monograph) | Penfill 3 mL cartridges and FlexTouch 3 mL pre-filled disposable pens. Pack sizes: 1 x 3 mL and 5 x 3 mL. |
| Storage | Not explicitly detailed in provided text snippet (refers to section 11), but standard insulin storage typically applies. |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Insulin Detemir |
|---|---|
| ATC code | A10AE05 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02412829 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2412829 |
| Brand name | LEVEMIR FLEXTOUCH |
| Generic / active ingredient | INSULIN DETEMIR : 100 UNIT |
| Market authorization holder | NOVO NORDISK CANADA INC |
| Health Canada schedule | Schedule D |
| ATC code | A10AE05 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A10AE |
| Current status | CANCELLED POST MARKET |
| Status date | 04-Aug-2023 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Subcutaneous injection once or twice daily. If once daily, give with evening meal or at bedtime. Titrate based on pre-breakfast plasma glucose. Do not mix with other insulins.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to the drug or any ingredient; during episodes of hypoglycemia.
Warnings and precautions
Hypoglycemia is the most common adverse effect. Do not administer IV or in infusion pumps. Do not mix with other insulins. Rotate injection sites to avoid lipodystrophy/cutaneous amyloidosis.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
0 of 2 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| LEVEMIR PENFILL | 100 UNIT | SOLUTION | NOVO NORDISK CANADA INC | DORMANT | 02271842 |
2 · Same class — other molecules in ATC A10AE
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Insulin Glargine | BASAGLAR · LANTUS · SEMGLEE · TOUJEO DOUBLESTAR · +1 more | 11 | 8 | Yes |
| Insulin Icodec | AWIQLI | 3 | 3 | Yes |
| Insulin Degludec | TRESIBA | 3 | 3 | Yes |
| Insulin Glargine And Lixisenatide | SOLIQUA | 1 | 1 | Yes |
| Insulin Detemir | LEVEMIR FLEXTOUCH · LEVEMIR PENFILL | 2 | 0 | Not in Canada |
| Insulin (Human) | HUMULIN-U ULTRALENTE INJ 100UNIT/ML · NOVOLIN GE ULTRALENTE INJ SUS 100U/ML | 2 | 0 | Not in Canada |
| Insulin Degludec And Liraglutide | XULTOPHY | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A10A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A10AB | Insulin (Beef) · Insulin (Human) · Insulin (Pork) · Insulin Aspart · Insulin Glulisine · +1 more | 40 | 24 |
| A10AD | Insulin (Human) · Insulin Aspart · Insulin Lispro | 31 | 9 |
| A10AC | Insulin (Human) · Insulin (Pork) | 13 | 5 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is LEVEMIR FLEXTOUCH called?
The same molecule, Insulin Detemir, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Actrapid HM (ge) | Latin | South Africa |
| Insuman Rapid | Latin | Norway |
| Humulin NPH | Latin | Norway |
| Humulin NPH KwikPen | Latin | Norway |
| Insuman Infusat | Latin | Norway |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.